ABO

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Wednesday, January 13, 2021 - 11:01pm

The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.

Key Points: 
  • The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.
  • Based on the data from these trials, ImmunityBio is conducting a pivotal, three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.
  • A randomized Phase 2 study (QUILT 88, Cohorts A and B) for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.
  • On the basis of our initial studies, we initiated our QUILT 88 randomized trials in metastatic pancreatic cancer and are pleased to present today those findings, including Cohort C survival rates.

DGAP-News: ABO Wind AG specifies further details on announced capital increase

Monday, November 16, 2020 - 1:12pm

- Free float increases to up to 38 percent; families of company founders retain majority

Key Points: 
  • - Free float increases to up to 38 percent; families of company founders retain majority
    ABO Wind AG has specified further details regarding the capital increase announced on November 11, 2020 .
  • The Supervisory Board of ABO Wind AG today approved the resolution of the Managing Board to increase the company's share capital by up to a nominal amount of 550,000 euros by issuing up to 550,000 new shares.
  • ABO Wind attaches great importance to a strong financial basis and an equity ratio of at least 40 percent.
  • With the planned capital increase, the free float of the ABO Wind share will grow to up to 38 percent.

DGAP-News: Nordex SE: The Nordex Group receives order for 43 MW from ABO Wind from Finland

Thursday, June 18, 2020 - 7:01am

The Nordex Group has received an order from its major customer ABO Wind for the supply and installation of nine N149/4.0-4.5 turbines for the Finnish project "Kokkoneva".

Key Points: 
  • The Nordex Group has received an order from its major customer ABO Wind for the supply and installation of nine N149/4.0-4.5 turbines for the Finnish project "Kokkoneva".
  • In 2019, ABO Wind was awarded the contract to operate the "Kokkoneva" wind farm in the first technology-neutral tender for renewables in Finland.
  • "This underlines that we are one of the leading project developers in Finland," says Aapo Koivuniemi, Managing Director of ABO Wind Oy, the Finnish subsidiary of ABO Wind.
  • ABO Wind is since 15 years a long-standing customer of the Nordex Group with wind farm projects in Germany, France, Ireland and Finland so far.

DGAP-News: ABO Wind AG: Internationalisation ensures success

Tuesday, June 9, 2020 - 10:01am

ABO Wind looks back on a successful financial year 2019.

Key Points: 
  • ABO Wind looks back on a successful financial year 2019.
  • The ABO Wind group currently employs 642 employees, one hundred more than in the previous year.
  • ABO Wind is now working on projects with a total rated output of around twelve gigawatts.
  • In 2019, ABO Wind installed for the first time solar systems in Hungary and Greece, and sold them in 2020.

COVID-19: LifeDNA and University of Hawai'i Collaborate on Studying Why Certain Populations Are Hit Harder

Tuesday, April 7, 2020 - 10:00pm

"COVID-19 has upended daily life for citizens around the globe," said Cyril Moukarzel, CEO of LifeDNA, Inc. "Based on genetics, certain individuals and populations may be impacted more severely.

Key Points: 
  • "COVID-19 has upended daily life for citizens around the globe," said Cyril Moukarzel, CEO of LifeDNA, Inc. "Based on genetics, certain individuals and populations may be impacted more severely.
  • LifeDNA's scientists are working tirelessly to add to the body of knowledge regarding the effect of these genetic variations."
  • Honolulu-based LifeDNA is collaborating with molecular epidemiologist Maarit Tiirikainen, Ph.D., Associate Professor at the University of Hawai'i at Mnoa.
  • "Epidemiological studiesso-called Genome Wide Association Studies (GWAS)indicate that populations carry different variants of the ACE2 gene.

Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Wednesday, February 26, 2020 - 1:00pm

NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Joo Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 11:00 a.m.

Key Points: 
  • NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Joo Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 11:00 a.m.
  • A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website, www.abeonatherapeutics.com , and an archived replay will be accessible for up to 30 days.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.
  • The Companys portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively.

Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposiumâ„¢

Wednesday, February 12, 2020 - 7:15pm

Abeona licensed the AAV9-based gene therapy technology underpinning ABO-102 and ABO-101 from AWRI at Nationwide Childrens where it was developed.

Key Points: 
  • Abeona licensed the AAV9-based gene therapy technology underpinning ABO-102 and ABO-101 from AWRI at Nationwide Childrens where it was developed.
  • In total, the new results continue to show that early treatment with ABO-102 can help preserve neurodevelopment in children with MPS IIIA.
  • For ABO-101, the reductions in disease-specific biomarkers are encouraging and demonstrate a clear biologic effect, which parallels that seen in the MPS IIIA study.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.

Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

Monday, October 21, 2019 - 2:15pm

The Companys clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively.

Key Points: 
  • The Companys clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively.
  • The Companys portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively.
  • Its preclinical assets include ABO-401, which uses the novel AIM AAV vector platform to address all mutations of cystic fibrosis.
  • Abeona has received twenty regulatory designations from the FDA and EMA for its pipeline candidates.

Goldfinch Bio Presents Methods to Mitigate Batch Effects in Whole Genome Sequencing Samples at ASHG 2019 Annual Meeting

Monday, October 21, 2019 - 12:00pm

These methods were described in an oral presentation on October 19th at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, TX.

Key Points: 
  • These methods were described in an oral presentation on October 19th at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, TX.
  • A copy of the abstract, entitled Mitigating Batch Effects in >23,000 WGS Samples for a Case-Control GWAS of Kidney Disease, is available on the Goldfinch Bio corporate website at https://www.goldfinchbio.com/publications .
  • Goldfinch Bios Kidney Genome Atlas is the most comprehensive patient registry to investigate the underlying mechanisms of kidney disease.
  • Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc. For more information about Goldfinch Bio, visit www.goldfinchbio.com .